Availability of funding for rare diseases coupled with growing collaborations to develop effective treatment for rare diseases will stimulate Europe esoteric testing market growth. The European Union is funding cross-border research regarding rare diseases through its Framework Programmes for Research and Technological Development along with complementary actions and projects funded via Health Programs. In addition, growing prevalence of rare disorders will boost Europe esoteric testing industry growth over the foreseeable future. According to the Graphical Research new growth forecast report titled “Europe Esoteric Testing Market Size By Test Type (Endocrinology, Infectious Disease & Immunology, Oncology, Toxicology, Neurology, Genomics), By Technology (Mass Spectrometry, Flow Cytometry, ELISA, Radioimmunoassay, Chemiluminescence, RT-PCR), Industry Analysis Report, Regional Outlook (Germany, UK, France, Italy, Spain, Russia, Poland, Sweden, The Netherlands, Portugal, Denmark, Norway), 2019-2025”, estimated to exceed USD 11.5 Billion By 2025.
Request for a sample of this report @ https://www.graphicalresearch.com/request/1171/sample
Growing awareness about early disease diagnosis will aid in Europe esoteric testing business expansion. Rare diseases are chronic and may be life-threatening. Thus, early diagnosis of such diseases is crucial to proceed with proper course of treatment before its progression. Also, the EURORDIS, a non-governmental patient-driven alliance of rare diseases is undertaking several initiatives to support undiagnosed rare diseases and address unmet needs of people suffering from such conditions, that will positively impact Europe esoteric testing industry growth during the forthcoming years.
However, high quality standard requirement for esoteric testing may impede Europe esoteric testing market growth over the coming years.
Infectious disease & immunology esoteric testing market was valued at USD 1.7 billion in 2018 and is estimated to grow at lucrative pace over the forecast years. Gradually rising prevalence of rare infectious diseases across the region will stimulate segmental growth. Furthermore, growing demand for advanced technological kits for diagnosis of infectious diseases will increase the adoption of infectious disease and immunology esoteric testing in the upcoming period.
Chemiluminescence esoteric testing is projected to progress at 10.2% CAGR over the estimated period. Robust segmental growth can be attributed to high quality of automation along with greater productivity of the technology. Chemiluminescence technology utilizes low analyte volume and is capable to deliver outcomes in lesser time duration. Such features are ideal and beneficial for molecular testing and will assist esoteric testing, thereby boosting segmental growth.
Make an Inquiry for purchasing this Report @ https://www.graphicalresearch.com/request/1171/inquiry-before-buying
Germany esoteric testing market held significant revenue size of about USD 1.2 billion in 2018. Increasing number of cases of rare diseases in Germany will act as high impacting factor for market growth. According to the National Action League for People with Rare Diseases, over 4 million people are directly affected by a rare or unique disease in the country. Additionally, the nation also has centralized core programs for research plans, national funding, screening, access to treatment, cross-border agreements and coordinated networks for rare disease management. Thus, rising awareness and presence of proper infrastructure for testing of rare diseases should spur German esoteric testing industry growth in the foreseeable future.
Major market players involved in the European esoteric testing market are Laboratory Corporation of America, Myriad Genetics, Opko Health and Quest Diagnostics. Firms are majorly focusing on bringing innovations in esoteric testing as well as undertaking strategic agreements to compete in the esoteric testing industry. For instance, in February 2019, Myriad Genetics, Inc. enhanced Prequel Prenatal Screen by including all 23 pairs of chromosomes instead of standard five previously tested. This is expected to help in improving the detection of aneuploidies by approximately 30%. Such developments will assist in improving birth outcomes and hence augment the business growth.
- Definition and forecast parameters
- Methodology and forecast parameters
- Data sources
- References & sources
Chapter 2.Executive Summary
- Europe esoteric testing industry summay, 2014 – 2025
- Regional trends
- Test type trends
- Technology trends
Chapter 3.Industry Insights
- Industry segmentation
- Industry outlook, 2014 – 2025
- Major factor analysis
- Technological advancements in esoteric testing
- Rising occurrence of complex and rare medical disorders in Europe
- Increasing prevalence of cancer and infectious diseases
- Growing demand for genomics and proteomics
- Rising awareness for early disease detection
- Restraints & challenges
- Stringent regulatory framework
- Types of business models
- Mobile lab services
- Full service diagnostics
- Reference/consulting services
- Regulatory landscape
- Porter’s analysis
- Competitive review, 2017
- PEST analysis
Segments we cover:
Europe Esoteric Testing Market, By Test type
- Infectious Disease & Immunology
Europe Esoteric Testing Market, By Technology
- Mass Spectrometry
- Flow Cytometry
Browse key industry insights from this Report @ https://www.graphicalresearch.com/table-of-content/1171/europe-esoteric-testing-market
About Graphical Research:
Graphical Research is a business research firm that provides industry insights, market forecast and strategic inputs through granular research reports and advisory services. We publish targeted research reports with an aim to address varied customer needs, from market penetration and entry strategies to portfolio management and strategic outlook. We understand that business requirements are unique: our syndicate reports are designed to ensure relevance for industry participants across the value chain. We also provide custom reports that are tailored to the exact needs of the customer, with dedicated analyst support across the purchase lifecycle.